SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense volatility as retail investors debate whether the current rally is a structural re-rating driven by AI-fueled memory demand or a speculative bubble prone to a sharp correction. The community remains deeply divided, with bulls pointing to fundamental AI tailwinds and potential supply chain disruptions at competitors, while bears warn of a looming technical reversal and excessive retail euphoria.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is attracting significant attention as community members discuss a potential take-private bid by Nelson Peltz's Trian Fund Management, which has fueled speculation of a major short squeeze given the stock's high short interest. Investors are actively debating the viability of a buyout, comparing the current valuation against growth initiatives like international expansion, while many look for a substantial price floor to shake out the bearish sentiment.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is experiencing heightened market activity following a strong quarterly earnings beat, fueling investor optimism regarding its transition from research to commercial hardware. While some members of the community express skepticism over its current revenue and valuation, bulls are actively focused on the company's strategic acquisitions and potential for a short squeeze amidst significant institutional interest.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors react to strong earnings and raised EBITDA guidance, while the market closely monitors the ongoing volatility in global LNG supply chains and Middle East geopolitical developments. The community remains focused on the company's aggressive growth, the impact of continued export terminal expansions, and the potential for a significant rerating as it outmaneuvers competitors.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending as investors react to promising preclinical data showing 100% tumor clearance in ovarian cancer models, fueling high volume and intense community speculation about potential short squeezes. Traders are actively debating the company's valuation, low-float structure, and the risks of potential future dilutions as the stock remains a focal point for momentum scalp strategies.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is experiencing intense volatility and social media debate driven by recent dilution concerns and regulatory questions surrounding its indirect Anthropic holdings. Despite this, many in the community remain focused on the fund's heavy pre-IPO exposure to high-profile assets like SpaceX, viewing the current price action as an accumulation opportunity ahead of anticipated liquidity events.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF ($DRAM) is surging as institutional investors pile into the sector to gain concentrated exposure to a structural memory chip supercycle driven by massive AI infrastructure demand. Community sentiment remains intensely bullish, with many traders viewing the current volatility and dip-buying opportunities as a key strategy to capitalize on the persistent supply crunch for high-speed memory.

Token Cat Ltd. operates as a holding company, which engages in the operation of an omni-channel automotive marketplace. It offers auto shows, group-purchase facilitation, and virtual dealership services. The company was founded by Wei Wen and Jian Chen Sun in 2010 and is headquartered in Beijing, China.

Token Cat Ltd. - ADR

TuanChe Ltd - ADR

TuanChe is seeing significant investor attention fueled by a low float, a pivot toward a crypto asset investment strategy, and a recent partnership announcement. The community is actively debating its potential for volatility, comparing it to other high-momentum Chinese small-caps and noting its thin trading structure.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing extreme volatility as traders weigh explosive momentum against concerns that leveraged decay and historical overbought conditions are setting the stage for a major market reversal. The community remains deeply polarized, with bulls leaning into aggressive AI-driven growth narratives while bears argue that massive retail participation and record-setting RSI levels signal an imminent and structural collapse.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Semiconductor stocks are seeing extreme volatility and record-high RSI levels, fueling intense debate among traders over whether this marks a sustainable AI-driven bull run or a dangerous bubble primed for a collapse. Community discussion is dominated by warnings of volatility decay in leveraged ETFs like SOXS and SOXL, while traders debate the timing of a potential sector correction versus continued momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>ABCL635 is being developed as a non-hormonal treatment for menopause-related vasomotor symptoms such as hot flashes.</li><li>ABCL is pivoting to become a fully integrated clinical-stage biotech that develops and owns its own high-value medicines.</li><li>According to data from Koyfin, 8 of the nine analysts covering ABCL stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’</li></ul>Shares of AbCellera Biologics Inc. (ABCL) continued their strong upward momentum on Friday, as investors gear up for the company’s first-quarter 2026 earnings report and a key clinical catalyst scheduled for Monday.ABCL shares closed up 9% on Friday and edged up 4% after hours. Overall, the stock clocked 18% gains this week, clocking its best week since the last week of February. &nbsp;<h2 class="st-heading-2">Upcoming Catalysts</h2>On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635 being developed as a non-hormonal treatment for menopause-related vasomotor symptoms such as hot flashes — an area with significant unmet medical need and an estimated multi-billion-dollar U.S. market opportunity.AbCellera spent years building an antibody discovery engine and generating revenue primarily through partnerships. It is now deliberately pivoting to become a fully integrated clinical-stage biotech that develops and owns its own high-value medicines. ABCL635 is the first real test of that shift.The positive sentiment was further reinforced this week by a regulatory filing showing that Baker Bros. Advisors, one of biotech’s most respected institutional investors, has increased its stake in AbCellera to 10.8% of outstanding shares.Wall Street, on average, now expects the firm to report first-quarter revenue of $5.84 million, above the $4.24 million reported in the corresponding quarter of 2025, in addition to a loss per share of $0.19.<h2 class="st-heading-2">Analyst Takeaways</h2>Earlier this week, Cantor Fitzgerald initiated coverage of AbCellera with an ‘Overweight’ rating and $7 price target. According to data from Koyfin, 8 of the nine analysts covering ABCL stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The 12-month average price target on the stock is $9.14, representing a potential upside of about 74% from the last close.<h2 class="st-heading-2">How Did ABCL Retail Traders React?</h2>On Stocktwits, retail sentiment around ABCL stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user opined that the biggest question running up to Monday is how strong the data will be.<stembedurl>https://www.stocktwits.com/StockMacroView/message/652806266</stembedurl>Another user voiced optimism for the catalysts driving the stock higher.<stembedurl>https://www.stocktwits.com/Stocktradesmoon/message/652742650</stembedurl><a href="https://stocktwits.com/symbol/ABCL">ABCL stock</a> has gained 161% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-qure-mrna-soar-on-reports-trump-will-fire-fda-marty-makary/cZX2uTvRegN">REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost 

On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635.

Equity

On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635.


Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

<ul class="summary-bullets"><li>CMPS stock has gained 41% this week, on track for its best week ever, if gains hold.&nbsp;</li><li>The voucher, aimed at fast-tracking therapies addressing major national health priorities, entitles Compass to enhanced FDA communications and a dramatically shortened review period for COMP360.</li><li>According to data from Koyfin, 11 of the 12 analysts covering CMPS rate it ‘Buy’ or higher, while one rates it ‘Hold.’</li></ul>Shares of Compass Pathways (CMPS ) climbed 5.5% on Friday, adding to a larger rally this week, after the company said that the U.S. Food and Drug Administration granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.CMPS stock has gained 45% this week, on track for its best week ever, if gains hold.The voucher, aimed at fast-tracking therapies addressing major national health priorities, entitles Compass to enhanced FDA communications and a dramatically shortened review period for COMP360, as little as 1-2 months after the application is filed.The company said that the agency has granted its rolling application request, allowing it to submit completed sections of its application rather than waiting for every section to be completed before review commences.Compass has conducted two late-stage studies for COMP360, generating data across more than 1000 patients with treatment-resistant depression. COMP360 may demonstrate effects as quickly as within one day after administration, with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses, Compass said.<h2 class="st-heading-2">Trump’s Push For Psychedelics</h2>President Trump, over the last weekend, signed an executive order directing health agencies to speed up research on drugs like psilocybin and ibogaine.Earlier on Friday, the FDA also stated it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD. However, Compass is the only publicly traded company in the U.S. among the three.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CMPS stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism for a further rally to $11.<stembedurl>https://www.stocktwits.com/texmade2/message/651311854</stembedurl>Another user opined that the market reaction to the priority review voucher announcement “feels too muted.”<stembedurl>https://www.stocktwits.com/ChristopherMcC/message/651309288</stembedurl>A third user termed the stock “super undervalued.”<stembedurl>https://www.stocktwits.com/Millionaire11/message/651299529</stembedurl>According to data from Koyfin, 11 of the 12 analysts covering CMPS rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The stock has a 12-month average price target of $22.08, implying a potential upside of about 141% from the last closing price.On Friday, B. Riley initiated coverage of Compass Pathways with a ‘Buy’ rating and $17 price target. The company is on track to develop the first FDA-approved oral psychedelic drug for treatment-resistant depression, but the stock trades in the bottom percentile of its psychedelic peers, the analyst told investors in a research note.&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> has gained 142% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lidr-stock-surging-today/cZBh9Q3Rec0">LIDR Stock Surges 35% – This Analyst Sees Potential Returns Of 4-5x Over Time</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CMPS On Track For Best Week Ever On FDA Push For Psychedelics

Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.

<ul class="summary-bullets"><li>The trial results were presented in a late-breaking oral session at the American Academy of Neurology (AAN) Annual Meeting in Chicago.</li><li>At 16 weeks, mobility improved significantly with eighty-one percent of patients achieving a clinically meaningful improvement, the company said.&nbsp;</li><li>Kyverna said the data support its plan to submit a biologics license application (BLA) to the FDA for miv-cel in SPS.</li></ul>Shares of Kyverna Therapeutics, Inc. (KYTX) jumped 24% after hours on Tuesday after the company said that its experimental one-time CAR-T cell therapy delivered rapid, lasting improvements in mobility and reversed disability in patients with stiff person syndrome (SPS) in a trial.The results were presented in a late-breaking oral session at the American Academy of Neurology (AAN) Annual Meeting in Chicago.<h2 class="st-heading-2">Trial Results</h2>In the phase-2 trial, 26 patients who had not responded well to standard off-label therapies received a single dose of Kyverna’s miv-cel.At 16 weeks, mobility improved significantly; eighty-one percent of patients achieved a clinically meaningful improvement. Two-thirds of those who needed walking aids at the start no longer required them. All 26 patients were able to stop chronic immunotherapies entirely, the company said. Disability, muscle stiffness, and sensitivity to spasms also improved markedly, it added.Miv-cel was generally well-tolerated. The most common side effect was a temporary drop in neutrophil cell counts that was manageable, Kyverna said.<h2 class="st-heading-2">What Next?</h2>Kyverna said the data support its plan to submit a biologics license application (BLA) to the FDA for miv-cel in SPS. If approved, it would become the first approved treatment for the condition and the first CAR-T therapy approved for any autoimmune disease.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around KYTX stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the company, highlighting the past experiences of its CEO Warner Biddle who previously worked with Kite Pharma. Kite was bought out by Gilead Sciences for $11.9 billion in 2017.<stembedurl>https://www.stocktwits.com/beststock/message/650960443</stembedurl>Another opined that miv-cel has a total addressable market of over $80 billion if its approved across multiple indications.<stembedurl>https://www.stocktwits.com/leon_dedrick/message/650960360</stembedurl><a href="https://stocktwits.com/symbol/KYTX">KYTX stock</a> has gained 11% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-gives-its-model-nemesis-lidar-vision-wallet-friendly-price-tag-unchanged/cZBIxJ6RI6N">NIO Gives Its Model Y Nemesis LiDAR Vision — Wallet-Friendly Price Tag Unchanged</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

KYTX Stock Soars After Hours: What’s Driving The Rally? 

Kyverna reported strong pivotal trial results for its one-time CAR-T therapy miv-cel, showing rapid mobility improvements and reversal of disability in patients with stiff person syndrome.

Should You Invest in the iShares Biotechnology ETF (IBB)?

<ul class="summary-bullets"><li>Legend, like Kelonia, develops and manufactures cell therapies to treat life-threatening diseases, particularly cancer.</li><li>Legend is best known for Carvykti, a CAR-T treatment for relapsed or refractory multiple myeloma, developed and marketed in collaboration with Johnson &amp; Johnson.</li></ul>Shares of Legend Biotech (LEGN) closed 18% higher on Monday, its best day since April 2023, following Eli Lilly and Company’s (LLY) buyout of its rival Kelonia Therapeutics for up to $7 billion.Lilly said earlier in the day that it has entered into a definitive agreement to acquire Kelonia to advance CAR-T cell therapies. Kelonia's lead program, KLN-1010, is an in vivo CAR-T therapy currently in early-stage studies for relapsed/refractory multiple myeloma.Under the terms of the deal, Lilly will pay Ketonia shareholders an upfront payment of $3.25 billion in addition to milestone payments. The transaction is expected to close in the second half of 2026.Legend, like Kelonia, develops and manufactures cell therapies to treat life-threatening diseases, particularly cancer. It is best known for Carvykti, a CAR-T treatment for relapsed or refractory multiple myeloma, developed in collaboration with Johnson &amp; Johnson (JNJ).Last month, Legend said that more than 10,000 patients have been treated with Carvykti and that the franchise achieved profitability for the full year 2025. Carvykti net trade sales came in at $1.9 billion for the year.<h2 class="st-heading-2">Wall Street Takeaway</h2>Following the deal announcement, RBC Capital reportedly reiterated an ‘Outperform’ rating and $62.00 price target on Legend Biotech, opining that it highlights large pharma interest in the CAR-T market, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://m.in.investing.com/news/stock-market-news/rbc-capital-reiterates-legend-biotech-stock-rating-on-pharma-interest-93CH-5346810?ampMode=1">report</a> from Investing.com. Legend has potential sales of $2.8 billion in 2026, according to RBC.H.C. Wainwright also reiterated a ‘Buy’ rating with a $50 price target citing progress across the company’s CAR-T therapy programs, as <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/stock-market-news/hc-wainwright-reiterates-legend-biotech-stock-rating-on-pipeline-progress-93CH-5345904">per</a> Investing. First-in-human data from the LUCAR-G39D in vivo cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma is expected to start rolling in during the second half of 2026, with Wainwright flagging ASCO 2026 conference in late May to in early June as a plausible venue for the first readout.According to data from Koyfin, 14 of 16 analysts covering LEGN rate it ‘Buy’ or higher while two rate it ‘Hold.’ The 12-month average price target on the stock is $57.23, presenting a potential upside of about 128% from last close.<h2 class="st-heading-2"> How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around LEGN stayed within the ‘extremely bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels.A Stocktwits user sounded optimistic for Johnson &amp; Johnson acquiring Legend to “not split the revenue” with Carvykti.<stembedurl>https://www.stocktwits.com/Realtrader77/message/650805222</stembedurl>Another voiced optimism for the company getting bought out for $41/ per share, presenting significant upside.<stembedurl>https://www.stocktwits.com/Stockseeking/message/650804814</stembedurl><a href="https://stocktwits.com/symbol/LEGN">LEGN stock</a> has fallen 22% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/jetblue-ceo-vows-strong-cash-pile-will-prevent-bankruptcy-in-2026-report/cZBdZIgRIzp">JetBlue CEO Vows Cash Pile Will Prevent Bankruptcy in 2026: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Legend Biotech Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

LEGN Stock Clocks Best Day In Three Years — What’s Driving The Rally?

After Eli Lilly and Company bought Kelonia to advance CAR-T cell therapies, retail traders are now speculating a buyout for Legend. 

<ul class="summary-bullets"><li>Anavex stated it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.</li><li>The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises office to move forward with marketing authorization preparations.</li><li>This comes two days after Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage.</li></ul>Anavex Life Sciences Corp. (AVXL) shares tanked more than 33% in Wednesday’s opening trade after the company announced that it has withdrawn its marketing authorization application for its Alzheimer’s drug, blarcamesine, in the European Union.Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.This comes two days after Anavex&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-soars-anavex-alzheimers-drug-blarcamesine-slows-brain-shrinkage/cZ3mhyrRI0F">reported</a> new data about blarcamesine, suggesting a slowdown in brain shrinkage.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AVXL">Anavex Life Sciences</a> trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Did Anavex Withdraw Application?</h2>Anavex stated that it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises (SMEs) office to move forward with marketing authorization preparations.“Anavex now has to take note of the differing assessment of the CHMP at the EMA and will consider the constructive feedback received from the CHMP and focus on gathering additional data and conducting further analyses to address the points raised by the CHMP,” the company stated.<h2 class="st-heading-2">New Blarcamesine Trial Data Suggests Slowdown In Brain Shrinkage</h2>Earlier this week, Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage. Brain shrinkage is a key marker of Alzheimer’s progression.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III programs, indicating that preservation of brain volume is associated with improved patient outcomes.The company said its trial data suggest patients with wild-type SIGMAR1 and COL24A1 genes may see greater clinical and structural benefits from blarcamesine.MRI biomarker analysis showed a strong and consistent link between reduced brain atrophy and improvements in cognition, daily activities, and overall clinical outcomes, Anavex said.<a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 21% year-to-date and 71% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 43% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lmt-stock-lockheed-martin-quadruple-precision-strike-missiles-production-iran-war/cZ3YFRyRIS9">Lockheed Martin To Quadruple Precision Strike Missile Output After First Combat Use In Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

<ul class="summary-bullets"><li>The company said that its trial data also show that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.</li><li>An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, Anavex said.</li><li>This includes cognition, activities of daily life, and global clinical cognitive and functional outcome.</li></ul>Anavex Life Sciences Corp. (AVXL) on Monday reported new data about its Alzheimer’s drug blarcamesine, suggesting a slowdown in brain shrinkage.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III program, indicating that preservation of brain volume is linked to improved patient outcomes. The drug remains investigational and has not been approved by regulators.<a href="https://stocktwits.com/symbol/AVXL">Anavex shares</a> were up more than 13% in Monday’s opening trade.<h2 class="st-heading-2">What Does The Data Show?</h2>Anavex stated that the new data points to a reduction in brain volume loss over time. Brain shrinkage is a key marker of Alzheimer’s progression.“The patient-friendly oral administration, the manageable side effects, and the clinical efficacy—particularly in the genetically defined ABCLEAR3 population—make blarcamesine, in conjunction with the associated biomarker signal, a promising drug candidate for patients with early-stage Alzheimer’s disease,” said Timo Grimmer, member of the Anavex Scientific Advisory Board.The company said that its trial data also shows that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, including cognition, activities of daily life, and global clinical cognitive and functional outcome.“The consistent relation between structural preservation of brain volume and functional outcomes further drives our dedication to developing a novel disease-modifying Alzheimer’s treatment with our oral blarcamesine,” said Anavex CEO Christopher U. Missling.<h2 class="st-heading-2">What Does Anavex Do?</h2>Anavex is a New York-based biopharmaceutical that is involved in the development of therapeutics for the treatment of various disorders, including Alzheimer’s disease, Parkinson’s disease, and schizophrenia, among others.The company’s preclinical studies of blarcamesine showed that the oral drug candidate has the potential to halt or reverse the course of Alzheimer’s disease.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user said that Anavex’s brain volume preservation data is “incredibly exciting.”<stembedurl>https://stocktwits.com/Logic102/message/648270407</stembedurl><a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is up 26% year-to-date, but down 54% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 41% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 23%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gold-price-recovers-as-trump-postpones-attack-on-iran-5-days-down-16-month/cZ3ma5TRI0O">Gold Price Recovers To $4,450 On Trump’s Iran Attack Pause – But Yellow Metal Is Still Down 15% In A Month After ‘Sell Everything’ Rout</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage

Anavex presented new data from its Phase IIb and Phase III blarcamesine programs, showing that preservation of brain volume is associated with improved patient outcomes.

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest IBB News

IBBiShares Biotechnology ETF